Carvedilol Tablet, Film Coated
Product Images NDC 71610-132

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 71610-132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 3.125 mg (71610 0132 53)

Label for Carvedilol 3.125 mg film-coated tablets, containing 60 tablets. The label includes the NDC 71610-0132-53 and indicates the product is repackaged by Aphena Pharma Solutions - Tennessee, LLC. Manufacturer is Aurobindo Pharma Limited, Hyderabad, India. Storage instructions and dispensing warnings are also visible.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)

A survival analysis Kaplan-Meier curve titled "Survival Analysis for COPERNICUS (Intent-to-Treat)" showing % mortality over months. Two lines represent placebo and Carvedilol groups, with mortality increasing over time, and a reported p-value of 0.004 indicating statistical comparison between groups.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)

A forest plot titled 'Effects on Mortality for Subgroups in COPERNICUS' showing hazard ratios for various patient subgroups including sex, age, race, diabetic status, ischemic status, heart rate, systolic blood pressure, spironolactone use, and all patients. Each subgroup is represented by a point estimate with horizontal confidence intervals plotted against a hazard ratio scale ranging from 0.0 to 2.0, with a vertical reference line at 1.0.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)

A survival analysis graph titled 'Survival Analysis for CAPRICORN (Intent-to-Treat)' showing mortality percentage over 24 months. The graph compares two groups, Placebo and Carvedilol, with percent mortality on the y-axis and months on the x-axis. The Carvedilol group shows lower mortality compared to the Placebo group over time, with a p-value of 0.03 indicating statistical significance.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)

A figure titled 'Effects on Mortality for Subgroups in CAPRICORN' presenting hazard ratios with confidence intervals for various patient subgroups. Subgroups include age, sex, timing post-myocardial infarction, prior beta-blocker use, Killip class, thrombolytic therapy, PTCA use, history of congestive heart failure, diuretic use, angina, hypertension, diabetes, heart rate, and systolic blood pressure. The horizontal axis ranges from 0.4 to 1.3 for hazard ratios.*

FDA Label Image

Chemical Structure (Carvedilol Str)

Chemical structure diagram of Carvedilol showing molecular bonds and functional groups as typically depicted for the active pharmaceutical ingredient in Carvedilol tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.